Pharvaris NV
PHVS25.120USD
+5.290+26.68%
Handelsschluss 07/11, 16:00（ET）Kurse um 15 Minuten verzögert
1.37BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Pharvaris NV Unternehmen
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Unternehmensinformationen
BörsenkürzelPHVS
Name des UnternehmensPharvaris NV
IPO-datumFeb 05, 2021
Gegründet am2015
CEOMr. Berndt Modig, CPA
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 05
AddresseEmmy Noetherweg 2
StadtLEIDEN
BörseNASDAQ Global Select Consolidated
LandNetherlands
Postleitzahl2333 BK
Telefon31712036410
Websitehttps://pharvaris.com/
BörsenkürzelPHVS
IPO-datumFeb 05, 2021
Gegründet am2015
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, May 15
Aktualisiert: Thu, May 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
Aktionäre
Aktionäre
Anteil
General Atlantic LLC
13.82%
Fidelity Management & Research Company LLC
9.90%
Foresite Capital Management, LLC
8.09%
VenBio Partners LLC
7.87%
Viking Global Investors LP
6.70%
Other
53.61%
Aktionärstypen
Aktionäre
Anteil
Private Equity
30.24%
Investment Advisor
18.67%
Venture Capital
17.96%
Hedge Fund
15.17%
Investment Advisor/Hedge Fund
7.22%
Individual Investor
6.25%
Research Firm
0.15%
Bank and Trust
0.05%
Pension Fund
0.04%
Other
4.26%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
124
52.17M
95.74%
-1.39M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
2023Q1
61
28.67M
84.75%
-3.62M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
General Atlantic LLC
7.53M
13.82%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.40M
9.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
4.41M
8.09%
+12.70K
+0.29%
Mar 31, 2025
VenBio Partners LLC
4.29M
7.87%
--
--
Mar 31, 2025
Viking Global Investors LP
3.65M
6.7%
--
--
Mar 31, 2025
EQT Life Sciences
3.56M
6.53%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
6.06%
--
--
Mar 31, 2025
VR Adviser, LLC
3.11M
5.71%
-107.41K
-3.34%
Mar 31, 2025
Deerfield Management Company, L.P.
2.02M
3.7%
--
--
Mar 31, 2025
Commodore Capital LP
1.91M
3.51%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.96%
ALPS Medical Breakthroughs ETF
0.73%
iShares MSCI Netherlands ETF
0.1%
iShares MSCI Europe Small-Cap ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares MSCI EAFE Small-Cap ETF
0.01%
Avantis International Small Cap Equity ETF
0.01%
First Trust IPOX Europe Equity Opportunities ETF
0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.96%
ALPS Medical Breakthroughs ETF
Anteil0.73%
iShares MSCI Netherlands ETF
Anteil0.1%
iShares MSCI Europe Small-Cap ETF
Anteil0.02%
SPDR S&P International Small Cap ETF
Anteil0.02%
iShares MSCI EAFE Small-Cap ETF
Anteil0.01%
Avantis International Small Cap Equity ETF
Anteil0.01%
First Trust IPOX Europe Equity Opportunities ETF
Anteil0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
